EF Hutton initiated coverage of Unicycive Therapeutics with a Buy rating and $5 price target. Unicycive, which is building a "comprehensive drug portfolio" for chronic kidney disease and acute kidney injury, could launch lead asset Renazorb, which the firm calls "the first innovative product in over a decade" for the treatment of hyperphosphatemia.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on UNCY:
- H.C. Wainwright bullish on Unicycive, says stock rise ‘well justified’
- Unicycive Therapeutics price target raised to $6 from $3 at Maxim
- Unicycive announces $130M financing to commercialize, launch Renazorb
- UNCY Skyrockets on Securing $130M Financing
- Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
